ReviewCancers2024
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Precision Medicine Gene Network Analyser: part I-cancer driver gene identification through network topology and ensemble machine learning.Genomics & informatics · 2026Article
- Site-Specific Genomic Markers Associated with Outcomes of PD-1 Blockade in Gastric and Esophagogastric Junction Cancer: Analysis of Japan's C-CAT Registry.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Article
- CD8Cancer science · 2026Article
- Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions.MedComm · 2026Review
- Genomic Landscape of Poorly Differentiated Gastric Carcinoma: An AACR GENIELife (Basel, Switzerland) · 2026Article
- Gene, genetics and genetic medicines in gastroenterology: Current status and its future.World journal of gastroenterology · 2026Review
- EBV-associated gastric carcinoma occurring one year after metabolic bariatric surgery: case report and literature review.Frontiers in oncology · 2026Article
- Efficacy of immune checkpoint inhibitor plus chemotherapy in ARID1A-mutated advanced gastric cancer.Therapeutic advances in gastroenterology · 2026Article
- DriverSub-SVM: a machine learning approach for cancer subtype classification by integrating patient-specific and global driver genes.BMC bioinformatics · 2025Article
- Descriptive Genomic Analysis of Ampullary Carcinoma Utilizing the AACR Project GENIE Dataset.Current issues in molecular biology · 2025Article
- Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos.Cancer medicine · 2025Article
- ARID1A mutation drives gastric tumorigenesis via activating type 2 immune dominant microenvironment.iScience · 2025Article
- ATR-CHK1 Axis Inhibitors in Gastric Cancer Treatment.International journal of molecular sciences · 2025Review
- A Novel Hypoxia-Immune Signature for Gastric Cancer Prognosis and Immunotherapy: Insights from Bulk and Single-Cell RNA-Seq.Current issues in molecular biology · 2025Article
- Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights.Cureus · 2025Review
- Relationship between the protein expression of ARID1A, ARID1B and ARID2 with the clinicopathological characteristics of colorectal cancer.Biomedical reports · 2025Article
- ARID1A and Its Impact Across the Hallmarks of Cancer.International journal of molecular sciences · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AT-rich interaction domain 1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.